The immunotherapeutic efficacy of the proposed vaccine approach (gDE7 + IL6-/- + 1MT) relied on the immune-cellular profile of the tumor microenvironment, including activation of myeloid cells and reduction of PMN-MDSC and Treg. The gene discussed is IL6; the disease is neoplasm.